🌟 As Dermatology Times celebrates its 45th anniversary, we invite you to join us on a journey through the most impactful milestones in dermatology’s history. We recently asked our Editorial Advisory Board to tell us who mentored them in the dermatology space and about the importance of mentoring others. #45YearsofDT https://lnkd.in/gJNn-iaj
About us
Dermatology Times is a leading news resource serving more than 16,000 dermatologists and other skin care professionals and focusing on the latest developments in dermatological practice, regulatory news, practice management, and new products. We strive to help practitioners understand and put into perspective developments that affect their profession and their business.
- Website
-
http://www.dermatologytimes.com
External link for Dermatology Times
- Industry
- Book and Periodical Publishing
- Company size
- 501-1,000 employees
- Headquarters
- Cranbury
- Type
- Public Company
Locations
-
Primary
Cranbury, US
Employees at Dermatology Times
Updates
-
🌟 PARTNER SPOTLIGHT: Spherix Global Insights took a deep dive into secukinumab versus adalimumab in #hidradenitissuppurativa treatment performance, finding that awareness and usage of secukinumab among US dermatologists is steadily rising. https://lnkd.in/gChUN8ki
Evaluating the Efficacy and Perception of HS Treatment Options
dermatologytimes.com
-
📚 STUDY FINDINGS: Treatment with oral dimethyl fumarate led to significant improvements of all criteria for disease classification upgrade criteria in patients with plaque #psoriasis. Even when discontinued prior to week 52 of the study, patients meeting the upgrade criteria for moderate to severe disease classification exhibited substantial improvements in involvement of physical areas and pruritus, among others. https://lnkd.in/gnM_MPmh
Oral Dimethyl Fumarate Improves All Disease Classification Criteria in Plaque Psoriasis
dermatologytimes.com
-
📚 STUDY FINDINGS: Type 1 diabetes mellitus is considered a risk factor for the development of #vitiligo. Furthermore, application of T1 diabetes-related measures could potentially provide novel ways to prevent or address vitiligo. https://lnkd.in/g_AX8rfk
Type 1 Diabetes is a Risk Factor for Vitiligo Development, Study Reports
dermatologytimes.com
-
In a series of Dermatology Times Case-Based Roundtable events, leading dermatologists and their local peers tackled some of the most challenging cases of #atopicdermatitis. Review insights from an event hosted by Robert Posnick, MD, in Merrimack. https://lnkd.in/ek8y8M_6
Clinical Insights Into Challenging Atopic Dermatitis Cases: Part 3
dermatologytimes.com
-
🗞 IN THE NEWS: Review our rundown of the latest headlines in dermatology from the past week, including racial disparities in hidradenitis suppurativa, Stanford Medicine's new Skin of Color program, and more. https://lnkd.in/gu5-kjX4
Derm In The News: July 14-20
dermatologytimes.com
-
🧬 New findings from the TRuE-AD3 phase 3 study highlight the hematologic laboratory safety results of twice-daily application of 1.5% ruxolitinib cream in children aged 2-11 years with mild to moderate #atopicdermatitis. 🌟 Linda Stein Gold, MD, elaborated on the study design, methodology, and the significance of the findings. https://lnkd.in/gQvwDzdS
Hematologic Safety of Ruxolitinib Cream in Children with Atopic Dermatitis
dermatologytimes.com
-
🚨NEW TODAY: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has submitted a supplemental New Drug Application to the US FDA for #roflumilast foam 0.3% (Zoryve) for the treatment of both scalp and body #psoriasis in adults and adolescents aged 12 and over. https://lnkd.in/g_uEf6nT
Arcutis Submits sNDA for Roflumilast Foam to FDA for Scalp and Body Psoriasis
dermatologytimes.com
-
📚 A new 'How to…' tool, developed collaboratively and hosted on the TARGET website, aims to assist pharmacy professionals in general practice with evidence-based strategies for #acne management. https://lnkd.in/g_HYtkVr
General Practice Evaluation of the TARGET Acne Toolkit
dermatologytimes.com
-
🗓 WEEKLY ROUNDUP: Review our recap of the latest news and studies in dermatology from last week, including data for repigmentation with ruxolitinib cream, a review of pediatric cutaneous Crohn disease, and more. https://lnkd.in/e93rEHd3
The Weekly Roundup: July 15-19
dermatologytimes.com